Summary
The purpose of this is to test the safety and effectiveness of an investigational chemotherapy agent in patients with persistent or recurrent endometrial cancer.
Key Facts
Lead Sponsor
Enrollment
Start Date
Study Type
Official Title
Interventions
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: * Diagnosis of advanced or metastatic endometrial carcinoma * Progressive disease after 1 cytotoxic chemotherapy regimen given for advanced/metastatic disease * At least one measureable tumor lesion * Adequate bone marrow, hepatic and renal function * Performance status ECOG 0 or 1 Exclusion Criteria: * Prior exposure to trabectedin * Known hypersensitivity to dexamethasone or to any of the components of trabectedin * Less than 4 weeks since last radiation therapy or since last dose of hormonal therapy, biological therapy, therapy with any investigational agent, or chemotherapy * History of another neoplastic disease unless in remission for more than 5 years * Known metastases (spread) of cancer to the central nervous system or other serious illness as specified in the protocol * Current pregnancy, lactation, or childbearing potential without adequate method of contraception.